MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response

Journal of Proteomics

Volumn 74, Issue 5, 2011, Pages 728-743

  Shetty, Vivekananda ^a   Sinnathamby, Gomathinayagam ^a   Nickens, Zacharie ^a   Shah, Punit ^a   Hafner, Julie ^a   Mariello, Lisa ^a   Kamal, Shivali ^a   Vlahovic', Gordana ^b   Lyerly, H Kim ^c   Morse, Michael A ^b   Philip, Ramila ^a  

^a Immunotope Inc   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

Epitopes; Immunoproteomics; Immunotherapy; Lung cancer; Mass spectrometry; QRT PCR

Indexed keywords

HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; SYNTHETIC PEPTIDE; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LUNG CANCER; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; LUNG NEOPLASMS; MALE; PEPTIDES; PROTEOMICS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79953331837     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.02.020     Document Type: Article

References (80)

1. Morse M.A., Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther 2010, 12:11-13.
2. Harao M., Hirata S., Irie A., Senju S., Nakatsura T., Komori H., et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008, 123:2616-2625.
3. Kawano K., Gomi S., Tanaka K., Tsuda N., Kamura T., Itoh K., et al. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res 2000, 60:3550-3558.
4. Yamada A., Kawano K., Koga M., Takamori S., Nakagawa M., Itoh K. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res 2003, 63:2829-2835.
5. Friedman R.S., Bangur C.S., Zasloff E.J., Fan L., Wang T., Watanabe Y., et al. Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen. J Immunol 2004, 172:3319-3327.
6. Hirschowitz E.A., Yannelli J.R. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009, 6:224-232.
7. Romero P. Current state of vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008, 9(Suppl 1):S28-S36.
8. Shastri N., Schwab S., Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol 2002, 20:463-493.
9. Fortier M.H., Caron E., Hardy M.P., Voisin G., Lemieux S., Perreault C., et al. The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 2008, 205:595-610.
10. Admon A., Barnea E., Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2003, 2:388-398.
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
12. Rosenberg S.A. New opportunities for the development of cancer immunotherapies. Cancer J Sci Am 1998, 4(Suppl 1):S1-S4.
13. Boon T., Coulie P.G., Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997, 18:267-268.
14. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001, 50:3-15.
15. Schultze J.L., Vonderheide R.H. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001, 22:516-523.
16. Hoppes R., Ekkebus R., Schumacher T.N., Ovaa H. Technologies for MHC class I immunoproteomics. J Proteomics 2010, 73:1945-1953.
17. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993, 54:177-180.
18. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
19. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994, 152:163-175.
20. Barnea E., Beer I., Patoka R., Ziv T., Kessler O., Tzehoval E., et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 2002, 32:213-222.
21. Margulies D.H., Ramsey A.L., Boyd L.F., McCluskey J. Genetic engineering of an H-2Dd/Q10b chimeric histocompatibility antigen: purification of soluble protein from transformant cell supernatants. Proc Natl Acad Sci U S A 1986, 83:5252-5256.
22. Schneck J., Maloy W.L., Coligan J.E., Margulies D.H. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC. Cell 1989, 56:47-55.
23. Mage M.G., Lee L., Ribaudo R.K., Corr M., Kozlowski S., McHugh L., et al. A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity. Proc Natl Acad Sci U S A 1992, 89:10658-10662.
24. Kozlowski S., Takeshita T., Boehncke W.H., Takahashi H., Boyd L.F., Germain R.N., et al. Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature 1991, 349:74-77.
25. DeVito L.D., Mason B., Schneck J., Margulies D.H., Sollinger H.W., Burlingham W.J. Immunochemical analysis of a recombinant, genetically engineered, secreted HLA-A2/Q10b fusion protein. Hum Immunol 1991, 32:125-133.
26. Corr M., Boyd L.F., Frankel S.R., Kozlowski S., Padlan E.A., Margulies D.H. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med 1992, 176:1681-1692.
27. Hunt D.F., Henderson R.A., Shabanowitz J., Sakaguchi K., Michel H., Sevilir N., et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992, 255:1261-1263.
28. Henderson R.A., Cox A.L., Sakaguchi K., Appella E., Shabanowitz J., Hunt D.F., et al. Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. Proc Natl Acad Sci U S A 1993, 90:10275-10279.
29. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994, 264:716-719.
30. de Jong A. Contribution of mass spectrometry to contemporary immunology. Mass Spectrom Rev 1998, 17:311-335.
31. Bonner P.L., Lill J.R., Hill S., Creaser C.S., Rees R.C. Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. J Immunol Methods 2002, 262:5-19.
32. Engelhard V.H., Brickner A.G., Zarling A.L. Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol Immunol 2002, 39:127-137.
33. Zarling A.L., Ficarro S.B., White F.M., Shabanowitz J., Hunt D.F., Engelhard V.H. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000, 192:1755-1762.
34. Pierce R.A., Field E.D., den Haan J.M., Caldwell J.A., White F.M., Marto J.A., et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 1999, 163:6360-6364.
35. Skipper J.C., Hendrickson R.C., Gulden P.H., Brichard V., Van Pel A., Chen Y., et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996, 183:527-534.
36. Schirle M., Keilholz W., Weber B., Gouttefangeas C., Dumrese T., Becker H.D., et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000, 30:2216-2225.
37. Flad T., Spengler B., Kalbacher H., Brossart P., Baier D., Kaufmann R., et al. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res 1998, 58:5803-5811.
38. Kao H., Amoscato A.A., Ciborowski P., Finn O.J. A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clin Cancer Res 2001, 7:773s-780s.
39. Ramakrishna V., Ross M.M., Petersson M., Gatlin C.C., Lyons C.E., Miller C.L., et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003, 15:751-763.
40. Casado-Vela J., Martinez-Esteso M.J., Rodriguez E., Borras E., Elortza F., Bru-Martinez R. iTRAQ-based quantitative analysis of protein mixtures with large fold change and dynamic range. Proteomics 2010, 10:343-347.
41. Wang W., Gulden P.H., Pierce R.A., Shabanowitz J., Man S.T., Hunt D.F., et al. A naturally processed peptide presented by HLA-A*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity. J Immunol 1997, 158:5797-5804.
42. Shafer-Weaver K., Sayers T., Strobl S., Derby E., Ulderich T., Baseler M., et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003, 1:14.
43. Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002, 62:5818-5827.
44. Milner E., Barnea E., Beer I., Admon A. The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol Cell Proteomics 2006, 5:357-365.
45. Luckey C.J., Marto J.A., Partridge M., Hall E., White F.M., Lippolis J.D., et al. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J Immunol 2001, 167:1212-1221.
46. Lev A., Denkberg G., Cohen C.J., Tzukerman M., Skorecki K.L., Chames P., et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 2002, 62:3184-3194.
47. Wang W., Man S., Gulden P.H., Hunt D.F., Engelhard V.H. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides. J Immunol 1998, 160:1091-1097.
48. Wahl A., Schafer F., Bardet W., Hildebrand W.H. HLA class I molecules reflect an altered host proteome after influenza virus infection. Hum Immunol 2010, 71:14-22.
49. Karunakaran K.P., Rey-Ladino J., Stoynov N., Berg K., Shen C., Jiang X., et al. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J Immunol 2008, 180:2459-2465.
50. Weinzierl A.O., Rudolf D., Hillen N., Tenzer S., van Endert P., Schild H., et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol 2008, 38:1503-1510.
51. Weinzierl A.O., Lemmel C., Schoor O., Muller M., Kruger T., Wernet D., et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics 2007, 6:102-113.
52. Stryhn A., Pedersen L.O., Holm A., Buus S. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur J Immunol 2000, 30:3089-3099.
53. Flyer D.C., Ramakrishna V., Miller C., Myers H., McDaniel M., Root K., et al. Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect Immun 2002, 70:2926-2932.
54. Chen Y., Low T.Y., Choong L.Y., Ray R.S., Tan Y.L., Toy W., et al. Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells. Proteomics 2007, 7:2384-2397.
55. Koshikawa K., Osada H., Kozaki K., Konishi H., Masuda A., Tatematsu Y., et al. Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. Oncogene 2002, 21:2822-2828.
56. Huang X., Shi Z., Wang W., Bai J., Chen Z., Xu J., et al. Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a. Biochem Biophys Res Commun 2007, 361:287-293.
57. Schonthal A.H. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett 2001, 170:1-13.
58. Sykulev Y., Joo M., Vturina I., Tsomides T.J., Eisen H.N. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996, 4:565-571.
59. Franco A., Tilly D.A., Gramaglia I., Croft M., Cipolla L., Meldal M., et al. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat Immunol 2000, 1:145-150.
60. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
61. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
62. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
63. Fairchild P.J., Wraith D.C. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today 1996, 17:80-85.
64. Gebreselassie D., Spiegel H., Vukmanovic S. Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 2006, 67:894-906.
65. Sinnathamby G., Lauer P., Zerfass J., Hanson B., Karabudak A., Krakover J., et al. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother 2009, 32:856-869.
66. Raez L.E., Fein S., Podack E.R. Lung cancer immunotherapy. Clin Med Res 2005, 3:221-228.
67. Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001, 60:433-441.
68. Hiroi N., Ito T., Yamamoto H., Ochiya T., Jinno S., Okayama H. Mammalian Rcd1 is a novel transcriptional cofactor that mediates retinoic acid-induced cell differentiation. EMBO J 2002, 21:5235-5244.
69. Gu J., Sun D., Zheng Q., Wang X., Yang H., Miao J., et al. Human Elongator complex is involved in cell cycle and suppresses cell growth in 293T human embryonic kidney cells. Acta Biochim Biophys Sin (Shanghai) 2009, 41:831-838.
70. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25:1195-1204.
71. Ng D.C., Lim C.P., Lin B.H., Zhang T., Cao X. SCG10-like protein (SCLIP) is a STAT3-interacting protein involved in maintaining epithelial morphology in MCF-7 breast cancer cells. Biochem J 2010, 425:95-105.
72. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001, 353:417-439.
73. Wang S.S., Esplin E.D., Li J.L., Huang L., Gazdar A., Minna J., et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 282:284-287.
74. Kotake Y., Zeng Y., Xiong Y. DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res 2009, 69:1809-1814.
75. Lovejoy C.A., Lock K., Yenamandra A., Cortez D. DDB1 maintains genome integrity through regulation of Cdt1. Mol Cell Biol 2006, 26:7977-7990.
76. Mullenders J., von der Saal W., van Dongen M.M., Reiff U., van Willigen R., Beijersbergen R.L., et al. Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res 2009, 15:5811-5819.
77. Qian H., Ji C., Zhao S., Chen J., Jiang M., Zhang Y., et al. Expression and characterization of HSPC129, a RNA polymerase II C-terminal domain phosphatase. Mol Cell Biochem 2007, 303:183-188.
78. Li J., Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006, 6:45-54.
79. Suzuki T., Lu J., Zahed M., Kita K., Suzuki N. Reduction of GRP78 expression with siRNA activates unfolded protein response leading to apoptosis in HeLa cells. Arch Biochem Biophys 2007, 468:1-14.
80. Corrigall V.M., Bodman-Smith M.D., Fife M.S., Canas B., Myers L.K., Wooley P., et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 2001, 166:1492-1498.